SALEM, Ore. – Oregon, Washington and Idaho are among the 44 states splitting a $100 million settlement with pharmaceutical giant Abbott Labs. The agreement announced Monday resolves a dispute over the company's marketing of a drug called Depakote .
The medication is federally-approved to treat certain mental illnesses. But a multi-state investigation found that Abbott used a flawed study to promote the drug as a way to treat other illnesses, such as schizophrenia and dementia.
"When they subsequently did a second study, that study found that Depakote was not effective to treat schizophrenia," says David Hart a prosecutor with the Oregon Department of Justice. "But they continued to promote using the weaker first study."
The settlement is part of a much larger $1.5 billion deal that Abbott Labs struck with the federal government. It resolves civil and criminal penalties relating to Depakote. In a statement the drug company said it cooperated fully during the investigation.
On the Web:
Oregon Department of Justice press release: http://www.doj.state.or.us/releases/2012/rel050712.shtml
Abbott Labs statement: http://www.abbott.com/news-media/press-releases/abbott-reaches-settlement-agreement-on-depakote.htm
Copyright 2012 Northwest News Network
9(MDAxNzgwMDc3MDEyMTQ4NzYzMzI5ZTVkMQ004))
